Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aldagen
Durham, North Carolina, United States
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
Aldagen developed technology for selecting stem cells with higher potency from adult sources using aldehyde dehydrogenase (ALDH). Their most advanced program, ALD-101, was a purified cord blood stem cell product for treating inherited metabolic diseases in pediatric patients that reached Phase III trials. They also developed ALD-201, which used patients' own bone marrow-derived stem cells for treating chronic heart failure, which completed Phase I trials.
- Therapeutic areas
- CardiovascularMetabolic DisordersHematologyOncologyNeurology
- Modalities
- Regenerative cell therapiesStem cell therapies
- Industry
- Biotech
Beyond the preview
Go deeper on Aldagen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aldagen.